Science and Research

eVolve Meso 2 (D798MC00002): Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (eVOLVE-02)

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in partic-ipants with advanced/metastatic solid tumors.

Study details
Study-ID: NCT06535607, 2025-523947-36
Study-ID: NCT06535607, 2025-523947-36
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, TLRC
DZL Participating Sites: ARCN, TLRC
Start Date: 22.08.2024
Completion Date: 30.11.2028
Status: Recruiting
Status: Recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.